The venture’s pre‑seed AI/biotech focus aligns with the MVK’s aim to accelerate early‑stage medtech and drug‑discovery companies in the UK. The programme’s non‑dilutive funding and intensive 4‑month support match the founder’s need for capital, compute resources, and industry connections.